JPH0436244A - Antiviral agent - Google Patents
Antiviral agentInfo
- Publication number
- JPH0436244A JPH0436244A JP2143944A JP14394490A JPH0436244A JP H0436244 A JPH0436244 A JP H0436244A JP 2143944 A JP2143944 A JP 2143944A JP 14394490 A JP14394490 A JP 14394490A JP H0436244 A JPH0436244 A JP H0436244A
- Authority
- JP
- Japan
- Prior art keywords
- water
- eucalyptus
- extract
- hot
- extraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003443 antiviral agent Substances 0.000 title claims abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 21
- 239000000284 extract Substances 0.000 claims abstract description 12
- 244000166124 Eucalyptus globulus Species 0.000 claims abstract description 10
- 241000725303 Human immunodeficiency virus Species 0.000 claims abstract description 7
- 241000700605 Viruses Species 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 7
- 239000002023 wood Substances 0.000 abstract description 10
- 208000015181 infectious disease Diseases 0.000 abstract description 8
- 238000000605 extraction Methods 0.000 abstract description 6
- 235000013312 flour Nutrition 0.000 abstract description 6
- 239000003795 chemical substances by application Substances 0.000 abstract description 5
- 201000010099 disease Diseases 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 239000002994 raw material Substances 0.000 abstract description 4
- 230000009385 viral infection Effects 0.000 abstract description 4
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 abstract description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 3
- 208000036142 Viral infection Diseases 0.000 abstract description 3
- 239000003729 cation exchange resin Substances 0.000 abstract description 3
- 241001430294 unidentified retrovirus Species 0.000 abstract description 3
- 125000000129 anionic group Chemical group 0.000 abstract description 2
- 230000002209 hydrophobic effect Effects 0.000 abstract description 2
- 229920005610 lignin Polymers 0.000 abstract description 2
- 238000003809 water extraction Methods 0.000 abstract description 2
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 abstract 1
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 abstract 1
- 208000030507 AIDS Diseases 0.000 description 10
- 238000000034 method Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241001236215 Pinus parviflora Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000018099 immunodeficiency 7 Diseases 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
【発明の詳細な説明】
〔産業上の利用分野〕
本発明は、ウィルス病、特にエイズ（ＡＩＤＳ）の予防
、治療等に有用な抗ウィルス剤及びこれを用いたウィル
ス感染予防並びに治療方法に関するものである。さらに
詳しく言うと本発明はユーカリを熱水或は水抽出するこ
とにより得られる抽出物の利用方法に関するものであり
、これをウィルス感染、特にレトロウィルス、さらに言
えばエイズウィルス感染による疾病の予防や治療に医薬
原料として利用しようとするものである。[Detailed Description of the Invention] [Industrial Application Field] The present invention relates to an antiviral agent useful for preventing and treating viral diseases, particularly AIDS (AIDS), and a method for preventing and treating viral infection using the same. It is. More specifically, the present invention relates to a method for using an extract obtained by extracting eucalyptus with hot water or water, and is used to prevent diseases caused by viral infections, particularly retroviruses, and more specifically, AIDS virus infections. It is intended to be used as a medicinal raw material for treatment.
〔従来の技術及び発明が解決しようとする課題〕ＨＩＶ
（Ｈｕｍａｎ Ｉｍｍｕｎｏｄｅｆｉｃｉｅｎｃ７
Ｖｉｒｕｓｕ ）はヒトのレトロウィルスでヒトのヘ
ルパーＴ細胞に特異的に感染し免疫阻害を引き起こすこ
とが知られている。この感染によって、後天性免疫不全
症候群（ａｃｑｕｉｔｅｄ ｉｍｍｕｎｅ ｄｅｌｉｃ
ｉｅｎｃ７ｓ７ｎｄｒｏｍｅ）に陥りその結果、いろい
ろな外部からの感染に対する抵抗力がなくなることで致
死を招く。[Problems to be solved by conventional techniques and inventions] HIV
(Human Immunodeficiency 7
Virus is a human retrovirus that is known to specifically infect human helper T cells and cause immune inhibition. This infection causes acquired immunodeficiency syndrome (acquired immunodeficiency syndrome).
ienc7s7ndrome), resulting in loss of resistance to various external infections, leading to death.
現在、抗エイズウィルス剤として種々の化合物が提案さ
れ、医薬品として開発されているが、効果、副作用等の
問題から決定的なものは得られておらず世界中で検討が
続けられている。ところで、これらの抗エイズウィルス
剤のうちには、五葉松の検車抽出物のような植物成分か
ら開発されたものがある（特開平１−２３８５３３）。At present, various compounds have been proposed as anti-AIDS virus agents and are being developed as pharmaceuticals, but due to issues such as effectiveness and side effects, no definitive results have been obtained, and studies are continuing all over the world. By the way, some of these anti-AIDS virus agents have been developed from plant ingredients such as the extract of Goyomatsu (Japanese Patent Application Laid-open No. 1-238533).
しかしこれは検車という特殊な部位から取られたもので
あり原料的な制約が大きい。However, this material is taken from a special site such as vehicle inspection, and there are major restrictions regarding raw materials.
本発明者らは、種々の植物成分の抗エイズウィル作用に
ついて鋭意検討を重ねた結果、自然界に大量に存在する
ユーカリの木部、そのうちでもＥ、 ｄｅｇｌｕｐｌａ
の木部の熱水及び水抽出物に抗エイズウイルス作用があ
ることを見いだし本発明を完成した。As a result of intensive studies on the anti-AIDS virus effects of various plant components, the present inventors found that the xylem of eucalyptus, which exists in large quantities in nature, was found to contain the xylem of eucalyptus, especially E. deglupla.
They discovered that hot water and aqueous extracts of the xylem of the tree have anti-AIDS virus effects, and completed the present invention.
本発明の抗つイスル剤はＥ、 ｄｅｇｌｕｐｌａの熱水
抽出物、特にこの抽出物に含まれる抗エイズウイルス性
の物質を有効成分として利用することを特徴とする。The anti-inflammatory agent of the present invention is characterized by utilizing a hot water extract of E. deglupla, particularly an anti-AIDS virus substance contained in this extract as an active ingredient.
Ｅ、 ｄｅｇｌｕｐｌａ以外のユーカリ木に於いても同
様の効果がみられるので利用可能であるが、特にＥ、
ｄｅｇｌｕｐｌａの作用が適してい条。Similar effects can be seen on eucalyptus trees other than E. deglupla, so it can be used, but especially E.
The action of deglupla is suitable.
本発明において用いる材は老木、若木、あるいは心材、
辺材どれでもよく特にこだわらない。The wood used in the present invention is old wood, young wood, or heartwood.
Any type of sapwood will do, and I'm not particular about it.
また抽出方法としては、水を用いたものであれば、冷水
、熱水あるいは加熱還流等特にこだわらない。木材は抽
出しやすいように細かく砕いたものを用いると収率良く
目的物を得ることが出来る。The extraction method is not particularly limited as long as it uses water, such as cold water, hot water, or heated reflux. If the wood is finely crushed for easy extraction, the desired product can be obtained with a high yield.
本発明において熱水抽出物はそのまま使用しても良いが
、さらに分別して、抽出物中に含まれる特に効果のある
成分のみを用いても良い。In the present invention, the hot water extract may be used as it is, but it may be further separated and only particularly effective components contained in the extract may be used.
本発明者らは、この抽出物に含まれる有効成分として使
用し得るものは水溶性の中ないしは高分子物質であると
推定している。The present inventors presume that what can be used as the active ingredient contained in this extract is a water-soluble medium- to high-molecular substance.
本発明において熱水抽出は木粉をそのまま抽出する前に
疎水性の樹脂類やリグニンを除くため予めアルコールや
ジオキサンで抽出した後に熱水抽出すると特に有効成分
の高い抽出物を得ることが出来る。In the present invention, hot water extraction removes hydrophobic resins and lignin before directly extracting the wood flour, so if the wood flour is extracted with alcohol or dioxane in advance and then extracted with hot water, an extract with particularly high active ingredients can be obtained.
またアルカリ水を用いることによっても有効成分を得る
ことが出来るが、この場合不純物も多く抽出されるため
単位抽出固形分当りの効果は低くなる。The active ingredient can also be obtained by using alkaline water, but in this case many impurities are also extracted and the effect per unit extracted solid content is lowered.
尚この有効成分はアニオン性の性質をもっているためカ
チオン交換樹脂を用いることにより濃縮することも可能
である。すなわち適当な条件下でカチオン交換樹脂に吸
着させた後、アルカリや塩を用いて溶出させることによ
り有効成分の多い区分を得ることが出来る。Since this active ingredient has anionic properties, it can also be concentrated by using a cation exchange resin. That is, by adsorbing it on a cation exchange resin under appropriate conditions and eluting it with an alkali or salt, a fraction containing a large amount of active ingredients can be obtained.
以下本発明を一実施例をもって説明するが本発明はこれ
に限定されるものではない。The present invention will be described below with reference to an example, but the present invention is not limited thereto.
Ｅｕｃａｌｉｐｕｌｕｓ ｄｅｇｌｕｐｌａの成木チッ
プ１００ｇをウイレーミルで６ａメツシユスの木粉にし
た後イソプロビールアルコール１１をくわえ２４時間撹
拌抽出後ン濾過、これを２回繰り返した。100 g of adult Eucalipulus deglupla chips were made into 6a Metsius wood flour using a Wiley mill, and 11 isoprobil alcohol was added to the mixture, followed by stirring and extraction for 24 hours, followed by filtration, and this process was repeated twice.
残渣木粉を乾燥後これに８０％ジオキサン水溶液１１を
加え４８時間撹拌抽出、濾過をやはり２回繰り返した。After drying the residual wood flour, an 80% dioxane aqueous solution 11 was added thereto, and the extraction with stirring for 48 hours and filtration were repeated twice.
残渣木粉を再び乾燥後水１１を加え８０℃で２４時間抽
出、これを濾過し炉液を濃縮後凍結乾燥し粉末９１０■
（試料Ａ）をえた。このものについて以下に示した方法
で抗エイズウイルス試験を行った。After drying the residual wood flour again, water 11 was added and extracted at 80°C for 24 hours. This was filtered, and the furnace liquid was concentrated and freeze-dried to obtain a powder of 910 cm.
(Sample A) was obtained. An anti-AIDS virus test was conducted on this product using the method shown below.
ＭＴ−４細胞中での旧Ｖ−１複製阻害効果ＭＴ−４細胞
（ＩＸＩＯ’コ細胞数／ウェル）に種々の濃度の試料Ａ
存在下で旧Ｖ−１（）ＩＴＬＶ−１１１１１）をｍｏｉ
Ｏ，［１２で感染後４日間培養し生存細胞数をＭＴＴ
法で測定した。Inhibitory effect of old V-1 replication in MT-4 cells Sample A at various concentrations on MT-4 cells (IXIO'cocell number/well)
Old V-1 () ITLV-11111) in the presence of moi
O, [12] was cultured for 4 days after infection and the number of viable cells was determined by MTT.
It was measured by the method.
その結果本試料のＨＩＶ−１のＭＴ−４細胞に対する５
０％感染抑制濃度はｌｌｕｇ／ｍ！であった。尚本試料
の非感染！ｌ！Ｔ−４に対する５０％生育阻害濃度は１
θｈｇ／ｍｌであった。As a result, 5% of HIV-1 of this sample against MT-4 cells.
0% infection inhibition concentration is llug/m! Met. This sample is non-infectious! l! The 50% growth inhibition concentration for T-4 is 1
It was θhg/ml.
つぎにこの試料１００ｍｇ／ｌＱｍｌを］ ０ ［１ｍ
ｌ容の炭酸型ＤＥＡＥセルロファインＡＭ陰イオン交換
樹脂カラム（チッソ株式会社製）に吸着後水洗し未吸着
区分を除いた後１モルの炭酸ソーダで溶出して（る区分
を集め減圧濃縮乾固これを再度水に溶かし脱塩装置で脱
塩し試料４０■（試料Ｂ）をえた。Next, add 100 mg/lQml of this sample] 0 [1 m
After adsorption on a 1 volume carbonate-type DEAE Cellulofine AM anion exchange resin column (manufactured by Chisso Corporation), it was washed with water to remove the unadsorbed fraction, and then eluted with 1 mol of sodium carbonate (the fraction was collected and concentrated to dryness under reduced pressure. This was dissolved in water again and desalted using a desalting device to obtain sample 40 (sample B).
このものの５０％感染抑制濃度は４υｇ／ｍｌ、 ５０
％細胞生育阻害濃度は１００１１ｇ／ｍ１以上であった
。The 50% infection inhibition concentration of this substance is 4υg/ml, 50
The % cell growth inhibition concentration was 10011 g/ml or more.
エイズウィルスはヒトのＴ細胞に感染し免疫阻害を起こ
しその結果癌や各種感染症にかかり死に至る病であるが
本発明品はエイズウィルスの感染増殖を阻害するだけで
なく抗体生産能を増強する効果のあることもわかってい
る。The AIDS virus infects human T cells and inhibits the immune system, resulting in cancer and various infectious diseases that lead to death.The product of this invention not only inhibits the infection and proliferation of the AIDS virus, but also enhances antibody production. It is also known to be effective.
また原料的に大量に安価な入手することも可能であり、
有用なエイズウィルスによる疾病の予防、治療剤となる
ものである。It is also possible to obtain raw materials in large quantities at low cost.
It is a useful agent for preventing and treating diseases caused by the AIDS virus.
第１図は本発明品（実施例の試料Ｂ）の赤外チャート（
ＫＢｒ法）を示す。
手続補正書（自
手続補正書
（方
式）
％式％
１、事件の表示
平成２年
特許願
第１４３９４４号
１、事件の表示
平成２年
特許願
第１４３９４４号
発明の名称
２、発明の名称
抗
ウィルス剤
補正をする者
事件との関係Figure 1 shows an infrared chart (
KBr method). Procedural amendment (self-procedural amendment (method) % formula % 1, Indication of the case 1990 Patent Application No. 143944 1, Indication of the case 1990 Patent Application No. 143944 Title of the invention 2, Name of the invention Antivirus Relationship with the case of the person making the amendment
Claims (3)
含有することを特徴とする抗ウィルス剤。(1) An antiviral agent characterized by containing hot water or water extract of eucalyptus as an active ingredient.
ｕｐｔａである請求項１記載の抗ウィルス剤。(2) The type of eucalyptus is Eucalyptus degl.
The antiviral agent according to claim 1, which is upta.
２記載の抗ウィルス剤。(3) The antiviral agent according to claims 1 and 2, wherein the virus is the AIDS virus.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2143944A JPH0436244A (en) | 1990-06-01 | 1990-06-01 | Antiviral agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2143944A JPH0436244A (en) | 1990-06-01 | 1990-06-01 | Antiviral agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH0436244A true JPH0436244A (en) | 1992-02-06 |
Family
ID=15350690
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2143944A Pending JPH0436244A (en) | 1990-06-01 | 1990-06-01 | Antiviral agent |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0436244A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995019782A1 (en) * | 1994-01-20 | 1995-07-27 | Hoashi Masahito | Antiviral powder, antiviral extract, and pharmaceutical preparation containing said powder and/or said extract |
| JP2001069922A (en) * | 1999-09-03 | 2001-03-21 | Nippon Suisan Kaisha Ltd | Natural physiologically active substance effective for fish parasitic disease, and fish feed containing the same |
| US6267993B1 (en) | 1994-01-20 | 2001-07-31 | Masahito Hoashi | Plant-derived powder and an extract of the same |
| JP2009179577A (en) * | 2008-01-30 | 2009-08-13 | Lion Hygiene Kk | Antiviral agent |
-
1990
- 1990-06-01 JP JP2143944A patent/JPH0436244A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995019782A1 (en) * | 1994-01-20 | 1995-07-27 | Hoashi Masahito | Antiviral powder, antiviral extract, and pharmaceutical preparation containing said powder and/or said extract |
| US6267993B1 (en) | 1994-01-20 | 2001-07-31 | Masahito Hoashi | Plant-derived powder and an extract of the same |
| JP2001069922A (en) * | 1999-09-03 | 2001-03-21 | Nippon Suisan Kaisha Ltd | Natural physiologically active substance effective for fish parasitic disease, and fish feed containing the same |
| JP4530307B2 (en) * | 1999-09-03 | 2010-08-25 | 日本水産株式会社 | Fish parasite therapeutic agent, method of use and use |
| JP2009179577A (en) * | 2008-01-30 | 2009-08-13 | Lion Hygiene Kk | Antiviral agent |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH06502413A (en) | Proanthocyanidin polymer with antiviral activity and method for producing the same | |
| DK145505B (en) | PROCEDURE FOR PREPARING A NITROGEN CONTAINING POLYSACCHARIDE | |
| KR20220156605A (en) | Application of Traditional Chinese Medicine Compositions in Preparation of Drugs for Treatment or Prevention of Coronavirus Infection | |
| US20020110600A1 (en) | Composition for treating symptoms of influenza | |
| JPH0436244A (en) | Antiviral agent | |
| JP2923660B2 (en) | Antiviral agent | |
| US20030054047A1 (en) | Pharmaceutical composition for the treatment of viral infection | |
| JPH03163025A (en) | Scutellaria-containing solution | |
| JPS63316731A (en) | Antiviral agent | |
| JPH04360838A (en) | Antiviral agent | |
| JP2005515266A (en) | Plant extracts that are active as immunostimulants | |
| US4132782A (en) | Method for suppressing herpes simplex virus | |
| RU2303993C1 (en) | Treatment and prophylaxis means applicable for treating young agricultural animals and method for preventing and treating calves for gastrointestinal tract diseases | |
| Inderbitzin | Studies on the permeability increasing factor (PIF) in skin extracts | |
| CN113980069B (en) | Method for extracting geraniin from rambutan peel and application thereof | |
| US7306816B1 (en) | Medicinal plant compositions of matter and method of preparation | |
| JPS6013004B2 (en) | Production method of interferon inducer | |
| PH12018000449A1 (en) | A traditional chinese medicine composition for treating viral influenza and preparation method | |
| KR100295395B1 (en) | Antiviral pharmaceutical composition useful for prevention and treatment of a cold caused by influenza a virus and a functional food | |
| AU2021105105A4 (en) | Drug for treating esophageal squamous cell carcinoma, and preparation method and use thereof | |
| GB2229919A (en) | Composition for antiviral medicines comprising lignin derivatives | |
| US6800304B2 (en) | Anti-ulcer pharmaceutical composition and the preparation thereof | |
| JP3254567B2 (en) | Method for producing physiologically active substance from plant tissue and composition containing this substance | |
| JPH0222231A (en) | Composition for antiviral drug | |
| AT253118B (en) | Process for the production of an active substance of polypeptide nature with unspecific immunizing effect |